Edesa Biotech, Inc. financial data

Symbol
EDSA on Nasdaq
Industry
Pharmaceutical Preparations
Location
100 Spy Court, Markham, Ontario, Canada
State of incorporation
British Columbia, Canada
Fiscal year end
September 30
Former names
Stellar Biotechnologies, Inc. (to 5/30/2019)
Latest financial report
10-K - Q3 2024 - Dec 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 173 % -65%
Debt-to-equity 55.5 % +192%
Return On Equity -164 % -67.7%
Return On Assets -106 % -28.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 3.47M shares +9.57%
Common Stock, Shares, Outstanding 3.25M shares +5.59%
Entity Public Float 11.1M USD
Common Stock, Value, Issued 47.2M USD +1.27%
Weighted Average Number of Shares Outstanding, Basic 3.22M shares +9.93%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 2.88M USD -39.9%
General and Administrative Expense 4.13M USD -6.67%
Operating Income (Loss) -7.01M USD +23.9%
Nonoperating Income (Expense) 845K USD -0.43%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.67M USD +16%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -6.17M USD +26.3%
Earnings Per Share, Basic -0.52 USD/shares +23.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1M USD -81.5%
Assets, Current 1.68M USD -74%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 18.4K USD -79.9%
Intangible Assets, Net (Excluding Goodwill) 2.21M USD
Assets 3.81M USD -57.1%
Liabilities, Current 1.83M USD +0.6%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 1.83M USD -0.48%
Accumulated Other Comprehensive Income (Loss), Net of Tax -243K USD -13%
Retained Earnings (Accumulated Deficit) -58.6M USD -11.8%
Stockholders' Equity Attributable to Parent 1.98M USD -71.9%
Liabilities and Equity 3.81M USD -57.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.41M USD +21.5%
Net Cash Provided by (Used in) Financing Activities 306K USD -89.5%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares, Issued 3.25M shares +5.59%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.09M USD -193%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.04M USD -80.7%
Deferred Tax Assets, Valuation Allowance 18.1M USD +9.77%
Deferred Tax Assets, Gross 18.2M USD +8.99%
Operating Lease, Liability 19.9K USD -79%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.2M USD +26%
Lessee, Operating Lease, Liability, to be Paid 20K USD -79.9%
Property, Plant and Equipment, Gross 52.5K USD 0%
Operating Lease, Liability, Current 19.9K USD -73.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 20K USD -0.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 20K USD -74.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 152 USD
Additional Paid in Capital 13.6M USD +4.12%
Operating Leases, Future Minimum Payments, Due in Two Years 79.9K USD +28.3%
Amortization of Intangible Assets 30K USD 0%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 59.9K USD
Deferred Tax Assets, Net of Valuation Allowance 126K USD -45.9%
Operating Leases, Future Minimum Payments, Due in Three Years 20K USD -3.78%
Operating Leases, Future Minimum Payments Due 160K USD +92.4%